Good day everyone, and welcome to the Vivos Therapeutics Second Quarter 2021 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow management’s remarks. This conference call is being recorded and a replay of today’s call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days. I will now hand the call over to Mr. Edward Loew, Vivos' Investor Relations Officer for introductions and the reading of the safe harbor statement. Please go ahead sir.

Thank you, operator. Hello, everyone, and welcome to Vivos Therapeutics Second Quarter 2021 Earnings Conference Call. A copy of the company's earnings press release is available on the Investor Relations section of our website at www.vivoslife.com. With us on today's call are Kirk Huntsman, Vivos' Chairman and Chief Executive Officer; and Brad Amman, Chief Financial Officer. Today, we'll review the highlights and financial results for the second quarter 2021 as well as more recent developments. Following these formal remarks, we will be prepared to answer your questions. I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, concerning future events. Words such as may, should, projects, expects, intends, plans, believes, anticipates, hopes, estimates and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the company's control. Actual results, including the results of Vivos' growth strategies, operational plans, future potential results of operations, or operating metrics, and other matters to be addressed by Vivos management in this conference call, may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in other disclosures contained in Vivos' filings with the Securities and Exchange Commission, including our second quarter 2021 10-Q, which is being filed today as well as in our most recent Form 10-K, which can also be accessed on the Vivos Investor Relations website. Except to the extent required by law, Vivos assumes no obligation to update statements as circumstances change. Now at this time, it is my pleasure to introduce, Kirk Huntsman, Chairman and CEO of Vivos. Kirk please go ahead.

Thanks Ed, and thank you everyone for joining us today on our second quarter 2021 earnings conference call. I'm excited to review our strong quarterly results and provide you with an update on our progress. Afterwards, our Chief Financial Officer, Brad Amman will review the highlights of our second quarter financial results. Following that, we'll be happy to take your questions. Our second quarter revenue results were quite strong, well ahead of our internal forecast and analyst estimates. This is due to the continued recognition and adoption of our Vivos System as a treatment for mild-to-moderate sleep apnea by members of the medical and dental communities as well as the benefits of our accelerated growth actions including a focus on strategic sales and marketing initiatives. We are also beginning to see revenue from beyond our core VIP enrollment revenue and appliances such as the value-added services we offer our VIPs and their patients as well as management revenue from our Medical Integration Division. As we are still relatively new to being a publicly traded company, I’d like to briefly recap our mission and strategy. Vivos is a growing medical technology company. Since the beginning, our mission has been to rid the world of obstructive sleep apnea or OSA. To realize our goal, Vivos focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing including OSA. For those of you not familiar with OSA, it is a chronic illness that impacts nearly one billion people globally and over 54 million in the United States. Over 80% of OSA sufferers are unaware they even have a condition, mostly because getting a proper clinical diagnosis is often confusing and costly especially for children. Because of these challenges, a majority of these sufferers remain undiagnosed and untreated. Those that are properly diagnosed are often left with extremely unattractive treatment options. These include having to wear a CPAP machine every night for the rest of their lives or subjecting themselves to costly, painful, and invasive surgery. At Vivos, we believe we have a better way to treat OSA than the current standard of care. Our highly effective Vivos System treatment is delivered within a comprehensive treatment ecosystem located within specially trained and equipped dental offices and supported by medical and other healthcare professionals. Through our growing network of Vivos' trained dentists, we offer an easy-to-use, low-cost screening test using our VivoScore ring recorder device powered by SleepImage that is dispensed by a dentist or a medical doctor. In our experience, about half of the patients tested with VivoScore will screen positive for OSA. Once diagnosed by a qualified physician, patients receive a complete evaluation workup performed on site by a trusted dentist. From there, they are given a clearly laid out and comprehensive treatment plan, offering them specific treatment options. Due to our efforts to educate healthcare and dental professionals, many are choosing Vivos' treatment, which the majority of patients complete in just 12 to 24 months. Upon completion, 97% of patients report having achieved their primary treatment objectives, and over one in four should see their OSA symptoms completely resolved. In most cases, no further treatment or intervention is required. We have made great progress in spreading the word about the benefits of Vivos' treatment options, through our target audience, the estimated 200,000 general dentists and dental specialists across the US and Canada. As of today, we have trained over 1,250 dentists across North America and internationally in the use and application of the Vivos System. Our dentists are enrolled in our Vivos Integrated Practice or VIP program, which offers training and other value-added services in connection with using the Vivos System. Turning now to the second quarter results. We achieved revenue growth of over 37% on a year-over-year basis and 30% over the first quarter of 2021, although I would like to note that the year-over-year comparison does reflect the drag on our revenue last year caused by COVID. We are thrilled with these results, which demonstrate the effects of our accelerated growth measures with rising enrollments by new VIP dentists and sequential quarter increases of 25% and 34% for products and services revenue respectively. Our increased revenues also reflect our emphasis on strategic sales and marketing initiatives, which have been designed to foster further recognition and adoption of the Vivos System by the medical and dental communities. Given our revenue and VIP growth during the second quarter, I think it's clear that these initiatives have positively impacted our performance. In addition to our top-line results, I'm pleased to report that for the second quarter of 2021, we recorded gross profit of approximately $3.6 million, a 33% increase compared to gross profit of approximately $2.7 million for the same period in 2020. We also achieved gross margin of 81% up sequentially compared to gross of 78% for the first quarter of 2021, although down slightly year-over-year. We also exceeded 19,000 total cases treated with the Vivos System and we ended the quarter with cash and cash equivalents of $34.2 million as of June 30, 2021. Brad will review our financial results with you in more detail. Needless to say, we are very pleased with these results. In addition to our core business lines, during the quarter, we also began to see strong demand for our new VivoScore diagnostic product and MyoCorrect therapy service. As I mentioned earlier, VivoScore is a home sleep test for both children and adults. Within 24 to 48 hours of testing, patients who test positive receive a telemedicine consult and confirming diagnosis and prescription for treatment from a qualified sleep specialist. Although we generate some revenue from VivoScore, we mainly view this product as a screening and diagnostic tool to get the dentists and their patients talking about and treating sleep apnea with the Vivos System. Our other new product, MyoCorrect, is a service where trained therapists will provide Vivos' trained dentists access to orofacial myofunctional therapy, also known as OMT, via telemedicine technology. Both of these offerings were launched in the second quarter, and I'm happy to report that the initial demand we received for both has exceeded our expectations. Based on this demand, we continue to expect these products will represent meaningful upside to our revenue potential as they build further momentum throughout the remainder of this year. The caveat here is that in Q3 and eventually moving into Q4, there are unknown impacts of the surging Delta variant of COVID on dental practices, patient visits, and consumer sentiment. In addition to our second quarter results, we have also made strides in other areas. In April, we announced the appointment of Dr. Mimi Guarneri, widely acclaimed as a leading integrative cardiologist, as an independent consultant, serving in the role of Medical Director of Clinical Education. As previously announced, Dr. Guarneri is also one of several physician owners of Vivos' first Pneusomnia Center, which opened in March and is located in Del Mar, California. In addition to her other responsibilities related to Vivos' first Pneusomnia Center, from which Vivos earned management fee revenue, her duties as Medical Director of Clinical Education include the promotion and expansion of Vivos' Medical Integration Division, which was launched in 2020 with the goal of creating strategic alliances between the medical and dental communities, so more medical doctors could work directly with dentists, including dentists who participate in the VIP program for treating sleep disorders in patients. Like VivoScore, we believe this will further the diagnosis and treatment of OSA with the Vivos System. Also, during the quarter, we completed an underwritten follow-on public offering of 4.6 million shares of common stock to support our continued growth. This included the exercise of the underwriter's option to purchase additional shares of common stock, for total net proceeds to the company of $25.4 million. Brad will discuss this in more detail later in today's call. Suffice to say, this has considerably strengthened our balance sheet, leaving us well positioned to continue our growth during the remainder of this year and beyond. We have also continued to publish exciting new findings from real-world data. Following the quarter end, in July, we unveiled new data from a patient survey commissioned by Vivos related to the use of the Vivos System. I'm pleased to report that our findings included a 97% Vivos patient satisfaction rate. In addition, study findings showed that over one in four Vivos patients experienced a complete resolution of their OSA from the Vivos treatment. After we initially made that particular announcement, there were some online pundits who suggested that these results weren't all that impressive. We emphatically disagree, as we are unaware of any other treatment modality for OSA that can make a similar claim without lifetime intervention or surgery. Moreover, we plan to continue to publish clinical results from ongoing and future studies as they come in and that we believe will continue to confirm the component benefits being realized by Vivos' patients and providers. Our firm belief is that patient clinical successes are the ultimate driver of our business model. The fact that nearly all surveyed patients reported they had achieved their desired treatment outcome is a powerful statement and is further proof of just how well the Vivos System works. More recently, I'm happy to share that just last week we opened the Vivos Institute International Training Center in Denver, Colorado. This 15,000 square foot state-of-the-art facility was established to augment our current highly acclaimed online training programs to offer advanced postgraduate education and training to dentists, dental teams, and other healthcare professionals from around the world in a live hands-on setting. Of course, curricula at the Institute include general courses on sleep and breathing disorders, as well as training in patient screening and understanding sleep tests, various therapeutic protocols and treatment options, medical billing, and best practices for in-office systems and integration of the Vivos System. The new training facility can accommodate 300 to 400 medical professionals per day. Here, we will continue to educate healthcare providers about OSA and Vivos' treatments for OSA within their practice areas, as well as provide dentists training on Vivos-related practice management tools. We are absolutely thrilled to establish this institute, which significantly increases our clinical training capacity while also enabling us to leverage the technology that we've built into the center to provide the highest quality training for dentists all across the world. You can learn more about the institute by going to www.thevivosinstitute.com. So in closing, the second quarter was a significant period for us. As the nation began to emerge from what now appears to be the first round of COVID infections and lockdowns, we achieved considerable revenue growth. This is the result of our accelerated growth actions, which we implemented by strategically deploying proceeds from our December IPO and May follow-on offerings. These actions not only drove our strong second quarter performance but have also established a strong foundation for our future growth potential in future quarters. In addition to the substantial uptick in VIP growth in appliance sales, which showcases continued adoption of the Vivos System, we have seen strong demand for our new product offerings, including our VivoScore diagnostic product and MyoCorrect therapy services. While these products were only recently launched in Q2, the strong demand we've seen supports our belief that these products represent substantial potential upside to our growth prospects. As we look to the future, working closely with our marketing partner, Osmond Marketing, we are launching aggressive social media and other marketing campaigns along multiple fronts to both providers and consumers. We believe these initiatives will help raise awareness of our brand and the compelling benefits of our treatment for people suffering from OSA. Now that our network of trained clinical dentists is beginning to fill out across the US and Canada, we have begun to reach out directly to a number of dental support organizations or DSOs. According to Morgan Stanley, over 8.3% of practicing dentists in 2019 belonged to DSOs in the United States. And that number is expected to grow to as many as 25% to 30% by 2025. These corporate dental practice operators control thousands of general dentistry and specialty practices throughout North America. We are currently in active discussions with several DSOs and hope to launch pilot programs with them by the end of the third quarter. In addition, we are piloting other initiatives that are intended to make it easier for more dentists to actively screen and refer their patients to VIP dentists. If successful, we will leverage the results to aggressively expand our service offering to a large number of dentists who may not be ready to become fully trained VIPs under our current program. This initiative could open the door for many more dentists to be exposed to Vivos and many more patients to receive the care they need for their OSA. Finally, we are actively engaged in forming additional strategic alliances and commercial relationships with industry partners and major health insurance payers as well as prominent leaders in the medical and dental professions. As those alliances and relationships come about, we will be making further announcements. We are extremely proud of all our accomplishments to date and are even more enthusiastic about our prospects for the future. We look forward to updating you on our progress as we continue to execute on our strategic growth initiatives. This concludes my opening remarks. Now, I'll pass the call on to Brad, who will review our financial results. Brad?

Thank you, Kirk, and good afternoon, everyone. Today, I'll review our second quarter 2021 financial results. We reported total revenue of approximately $4.5 million for the second quarter of 2021, an increase of 37.5% compared to approximately $3.3 million for the second quarter of 2020. This increase was related to revenue from appliance sales, VIP enrollments, billing intelligence service subscriptions, and initial management fees from our Medical Integration division or MID program. Revenue growth in 2021, when compared to 2020, is partially attributable to the negative impact of COVID-19 on our revenue during the second quarter of 2020. During the second quarter, we enrolled 73 VIPs and recognized revenue of approximately $2.4 million compared to 101 VIPs and recognized revenue of approximately $2.5 million during the same period last year. During the three months ended June 30, 2021, we sold 3,082 total oral appliance arches for a total of approximately $1.6 million, an increase from the three months ended June 30th, 2020, where we sold 1,266 total appliance arches for a total of approximately $600,000. The increase in appliance revenue is due to volume increases. For the six months ended June 30th, 2021, revenue increased 23% to more than $7.9 million compared to approximately $6.5 million for the six months ended June 30th, 2020. The increase was attributable to the same factors I mentioned earlier. During the first six months of 2021, we enrolled 126 VIPs for revenue of approximately $4.1 million compared to 133 VIPs and revenue of approximately $4 million for 2020. Additionally, our billing intelligence service revenues increased from approximately $300,000 for the first six months of 2020 compared to $400,000 for the first six months of 2021. During the first six months ended June 30th, 2021, we sold 5,652 oral appliance arches for revenue of approximately $2.9 million. For the six months ended June 30th, 2020, we sold 3,365 total oral appliance arches for revenue of approximately $1.9 million. The increase in appliance revenue is also due to volume increases for the six months ended June 30th, 2021. Gross profit was approximately $3.6 million for the second quarter of 2021 and approximately $6.3 million for the six months ended June 30th, 2021 compared to gross profit of approximately $2.7 million and approximately $5.1 million for comparable periods in 2020. Gross margin for the second quarter decreased slightly on a year-over-year basis to 81% compared to 83% during the last year's quarter. As during the height of the pandemic, many dentists enrolled into our VIP program and revenue shifted to higher-margin service revenue in the second quarter of 2020. Our business continues to be driven by high-margin service revenues including VIP enrollments and billing intelligence service revenues during both the three and six-month periods. Gross margin for both the first six months of 2021 and 2020 remain constant at 79%. Sales and marketing expense increased by approximately $1.2 million to $2.3 million for the six months ended June 30th, 2021 compared to approximately $1.1 million for the first six months ended June 30th, 2020. The increase was primarily due to an increase of approximately $700,000 in sales commissions on increased sales, approximately $0.5 million due to new marketing campaigns, updating marketing materials for investors and VIPs, and promotion of conferences and events taking place through June 30th, 2021. General and administrative expenses were approximately $6.1 million for the second quarter of 2021 and approximately $11.2 million for the six months ended June 30th, 2021 compared to approximately $3.5 million and approximately $7.7 million for the three and six months ended June 30th, 2020 respectively. The year-over-year increase was mainly due to higher expenses related to our increased personnel associated with supporting our sales growth as well as our status as a public company which started in late 2020. We realized these expenses were somewhat higher than what analysts had modeled, which reflects higher than anticipated revenues from our core business as well as the beginnings of revenue from our new products and services including VivoScore diagnostic product and the MyoCorrect therapy services as well as management fee revenue from our Medical Integration Division and sponsorship revenue, which accounted for approximately 1% of Q2 revenue. Net loss was approximately $4 million for the second quarter of 2021 compared to $1.4 million for the second quarter of 2020. The quarter-over-quarter increase was primarily due to higher G&A due to the factors that I mentioned earlier. Net loss for the six months ended June 30th, 2021 was approximately $7.4 million compared to $4 million for the first six months of 2020. Turning now to our balance sheet. In May, we enhanced our liquidity by completing a follow-on public offering of 4.6 million shares of common stock at a public offering price of $6 a share. The offering consisted of four million shares of our common stock as well as an additional 600,000 shares pursuant to the exercise in full of the underwriters' option to purchase additional stock. This generated aggregate net proceeds to the company of approximately $25.4 million. As for the rationale of the raise with greater-than-expected demand, we have seen for our recently launched VivoScore and MyoCorrect products, our management and Board of Directors determined this additional capital could be highly effective at this particular time. Since closing the offering, we have been making targeted investments such as additional sales people to support our growth. As evidenced by our second quarter results, we are already seeing the benefits of deploying this capital and expect to realize accelerated revenue growth through these new revenue streams during 2021 and beyond. At June 30, 2021, our cash and cash equivalents were approximately $34.2 million compared to cash and cash equivalents of approximately $14.1 million at March 31, 2021. With the proceeds from our December IPO and successful follow-on offering in May, we anticipate having ample financial resources to meet our capital requirements, fund our operations, and continue executing on our capital strategy for the foreseeable future. Moving forward, we will continue to aggressively expand our presence within the medical and dental communities with our expanded sales force and continue to introduce and educate health care and dental professionals on the benefits of the Vivos System for their patients. Our recent sales momentum is a strong testament to the increased awareness and adoption of the Vivos System throughout both the dental and larger health care communities. We continue to see strong demand and increased usage of Vivos' products and services both in our core business as well as our recently introduced products and services including VivoScore, MyoCorrect and the Medical Integration Division. We are hopeful that the current trends we are seeing in our business will provide momentum through the balance of 2021 and beyond. At the same time, we will remain prudent with our expenses and the management of working capital, maintaining strong expense management practices while continuing to deploy capital strategically to support continued growth. That concludes our prepared remarks. Now, I would like to turn the call over for questions. Cody, please go ahead.

Thank you. We'll take our first question from Alex Nowak with Craig-Hallum Capital. Please go ahead.

Great. Good afternoon everyone. Appreciate the update there. A lot of good color on the marketing spend. I just want to dig in there a little bit more. So the investments that you're making can you kind of mention how you're allocating it? Is it building out more teams on the sales side, more feet on the street? Is it more around the branding exercise? Is it more around patient and customer reach out there? Just any detail would be helpful.

Thank you for the question, Alex. We are taking a phased approach to this. Our primary focus has been to establish a national network across the US and Canada that allows doctors to treat patients. This initially required us to concentrate our marketing efforts primarily on the professional dental community. Last year, we expanded our efforts by introducing the Vivos System to the medical community. Our initial focus has been on professionals, but we are starting to shift our marketing strategy to include a more consumer-oriented approach. In the coming months, especially in the next few weeks, you will notice an increased emphasis on social media and more consumer-targeted media campaigns. We are transitioning to not only attract more providers but also to create brand awareness among consumers. As we expand our network, we want to ensure that when we invest in social media advertising, there are doctors ready to treat patients. This reflects our evolving strategy moving forward.

Yes. No, that's great. And Kirk, you obviously have a lot of experience on the DSO side. So I thought the commentary you had on the call and in the press release is really interesting there. So with the pilot program assuming that's successful, would it basically be like a large amount of VIPs coming on to the platform, if you did sign up one of these DSOs, or how would that look? And what are you thinking about timing in there?

That's an excellent question. To provide a bit of context, the DSO landscape includes several major players, which operate numerous dental offices across various states, as well as a new wave of smaller DSO operators with three to 50 locations. The DSO sector is growing. Notably, there hasn't been a DSO that has successfully implemented a dental sleep program, mainly due to the extensive training, capital equipment costs, and workflow changes required, along with challenges in medical billing. Previous attempts in this space have been very pragmatic. We are presenting a significantly different approach through our VivoScore devices. Our proposition does not require DSOs to invest heavily in training and equipment or disrupt their existing workflows. Instead, we are introducing the VivoScore product into their hygiene programs, allowing hygienists to screen patients for obstructive sleep apnea. Most patients will undergo screening, and about half are expected to test positive. At that point, we collaborate with our partner, Empower Sleep, who will provide diagnosis through telemedicine when necessary and prescribe treatment. This creates an ecosystem where patients are referred from DSOs to a local VIP office without requiring the DSO to train dedicated specialists. This method facilitates an easy implementation for DSOs, unlike any previous program offered. DSOs must consider how this initiative impacts their valuations, which are largely based on EBITDA. By increasing their EBITDA by a few percentage points, they boost their valuations during recapitalization. For them, this presents a compelling economic opportunity without the burden of capital expenditure. Vivos manages the program, provides the necessary devices, and offers simple training for their staff. If a DSO later wishes to incorporate specialists for additional economics from the program, they can easily do so. Ultimately, the VivoScore program is essential for driving our success and enhancing the DSO's reputation, as patients will see positive results and spread the word rapidly.

Alex, you also inquired about the sales teams. As you may remember, in Q1, we added our second sales team, and now we have three fully operational sales teams focusing on VIP enrollment.

Perfect. All right. I appreciate that. Just last question. Just any update on new studies we should be watching for? The Stanford study, when that should begin enrolling?

The Stanford study appears to be mired in some sort of just administrative black hole there at Stanford. We talk to them every week. They've had some turnover on their administrative staff and we're just waiting. We're ready to go. Everything has been agreed to. We're waiting to get that started. We're hopeful that that's going to happen at any time. And then, yes, there are other studies that are wrapping up and we'll have some announcements. I don't know when, but we'll have some announcements around that as soon as we get them ready to publish.

Okay. Great. Thanks for the update. Appreciate it.

Thank you. We'll take our next question from Scott Henry with ROTH Capital.

Thank you and good afternoon. I have a couple of questions. First, regarding the VivoScore, there were some significant percentage increases this quarter. Can you provide the absolute number of VivoScores released into the market during this period? Should we view that as the top of the funnel? Is it a leading indicator we should monitor to gauge traction? Thank you.

Yes, that’s a great question, Scott. The impact of VivoScore deployment in Q2 was relatively small. We began to receive shipments, although some were delayed due to a global shortage of various manufacturing components, which caused some delays in getting the equipment. We managed to deploy throughout Q2, so I wouldn’t emphasize that period too much. However, we successfully deployed in the last few weeks of the quarter, getting some units out and positioned, and they started generating some activity. Most of the significant deployment will occur in Q3. Brad, would you like to add anything to that?

Yes, the orders that we've placed include about 4,000 of the VivoScore diagnostic rings. And so that's really what's out there. And we're using those both for sales as well as for our sales and marketing team to use as demo devices as well with the dentist.

What we found is that one of the most effective ways to capture the attention of these doctors is by providing them with a demo ring. They take the test, realize they have sleep apnea themselves, and suddenly we have their full attention.

Okay. Shifting gears. Brad, since I've got you, you're adding sales teams. You had a strong Q2. Should we expect sequential revenue growth in Q3 and Q4 in the second half of the year?

We believe that the rings we are deploying will assist dentists as a tool for their patients. The outcome is still uncertain, but we are receiving numerous test results from those dentists. The next step is for them, after receiving positive or negative results for OSA, to review the positives and begin the Vivos System process with those patients. At this moment, we cannot predict how many will lead to increased revenue in the upcoming quarters, but that is our goal.

We are experiencing a significant increase in the number of tests. As Brad mentioned, these tests should theoretically lead to an increase in sales of devices. However, we are not far enough along to provide an estimate of how many positive tests will convert into clinical treatment cases. We are working on this and expect to have better visibility in Q3 and Q4.

Okay, that's helpful. Kirk, you mentioned MyoCorrect as a new revenue driver. Can you discuss the potential revenue it could generate? Is it projected to be a $5 million product at its peak, or could it exceed that in a couple of years? I'm trying to get a better understanding of that product's outlook.

The MyoCorrect therapy, also known as orofacial myofunctional therapy, has shown various benefits in our dental offices based on practitioner reports. We have observed shorter treatment durations, increased case acceptance and compliance, and improved treatment outcomes. These clinical advantages are significant. Currently, at the Vivos Institute, oral myofunctional therapy has become a central part of our training, complementing our standard Vivos System treatment curriculum. Graduates from our institute will be trained to incorporate oral facial myofunctional therapy into every Vivos case they handle. This approach could potentially add between $600 and $800 in additional gross revenue margin for each case. When a dentist submits a case for appliance ordering, there is an option to select oral facial myofunctional therapy, which directly impacts our revenue positively for each case. Moving forward, we anticipate an increase in the number of cases with higher margins for the company due to the implementation of orofacial myofunctional therapy. Overall, this leads to enhanced clinical outcomes, shorter treatment times, improved case acceptance and compliance, and greater margins per case, benefiting the company, patients, and providers alike.

Great. Thank you for that comment and thank you for taking the question.

You bet.

That does conclude today's question-and-answer session. I'd like to turn the conference back over to Mr. Huntsman, Chairman and CEO, for closing remarks.

Thank you, operator. I would like to thank everyone for participating and for joining us on today's call and for your continued interest in Vivos Therapeutics. We look forward to our progress with you in the future. Thank you very much and have a great day. Operator?

Thank you. That does conclude today's conference. Thank you for your participation.